Platelet glutamate receptors as a window into psychiatric disorders

Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS

Volumn , Issue , 2005, Pages 233-241

  Berk, Michael ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919849433     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-306-48644-X_15     Document Type: Chapter

References (50)

1. Almazov, V. A., Y. G. Popov, A. I. Gorodinsky, I. A. Mikhailova, S. A. Dambinova, and V. S. Gurevich (1988). The sites of high affinity binding of L-[3H] glutamic acid in human platelets: A new type of platelet receptor? Biokhimiia 53(5), 848-852.
2. Altamura, C. A., M. C. Mauri, A. Ferrara, A. R. Moro, G. D'Andrea, and F. Zamberlan (1993). Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 150, 1731-1733.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, text revision, 4th ed. American Psychiatric Association 2000, Washington DC.
4. Aparicio-Leagarza, M. I., B. Davis, P. H. Hutson, and G. P. Reynolds (1998). Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neuwsci. Lett. 241, 143-146.
5. Arora, R. C. and H. Y. Meltzer (1989). Increased serotonin 2 receptor binding as measured by 3H-LSD binding in blood platelets of depressed patients. Life Sci. 44, 725-734.
6. Arora, R. C. and H. Y. Meltzer (1993). Serotonin 2 receptor binding in blood platelets of schizophrenic patients. Psychiatry Res. 47, 111-119.
7. Bakish, D., P. Cavazzoni, J. Chudzik et al. (1997). Effects of serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol. Psychiatry 41, 184-190.
8. Berk, M., W. Bodemer, T. Van Oudenhove et al. (1994). Dopamine increases platelet intracellular calcium in bipolar disorder and controls. International Clin. Pharmacol. 9, 291-293.
9. Berk, M., H. Plein, and B. Belsham (2000). The specificity of the platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci. 66, 2427-2432.
10. Berk, M., H. Plein, and T. Czismadia (1999). Supersensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia. International Clin. Psychopharmacol. 14, 119-122.
11. Berk, M., H. Plein, and D. Ferreira (2000). Platelet glutamate supersensitivity in depression. Int. J. Neuropsychopharmacol. 3(Suppl 1), SI 12.
12. Berk, M., H. Plein, D. Ferreira, and B. Jersky (2001). Blunted adenosine A2a receptor function in platelets in patients with major depression. Eur. Neuropsychopharmacol. 11(2), 183-186.
13. Berman, R. M., A. Cappiello, A. Anand, D. A. Oren, G. R. Heninger, D. S. Charney et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354.
14. Biegon, A., A. Grinspoon, B. Blumenfeld et al. (1990). Increased serotonin 5HT2 receptor binding on blood platelets of suicidal men. Psychopharmacology (Berl) 100(2), 165-167.
15. Bouron, A and J. Y. Chatton (1999). Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Neuroscience 90, 729-736.
16. Breese, G., D. Knapp, and S. Moy (2002). Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: Potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neuwsci. Biobehav. Rev. 26(4), 441.
17. Butler, J., A. O'Halloran, and B. E. Leonard (1992). The Galway study of panic disorder II changes in some peripheral markers of noradrenergic and serotonergic function in DSM m-R panic disorder. J. Affect Disord. 26(2), 89-99.
18. Calabrese, J. R., C. I. Bowden, G. S. Sacks, J. A. Ascher, E. Monaghn, and G. D. Rudd (1999). A double blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar 1 depression. J. Clin. Psychiatry 60, 79-88.
19. Camacho, A. and J. E. Dimsdale (2000). Platelets and psychiatry: Lessons learned from old and new studies. Psychosom. Med. 62, 326-336.
20. Da Prada, M., A. M. Cesura, J. M. Launay et al. (1988). Platelets as a model for neurones? Experentia 44, 115-126.
21. Das, I., N. S. Khan, B. K. Puri, S. R. Sooranna, J. De Belleroche, and S. R. Hirsch (1995). Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem. Biophys. Res. Commun. 212(2), 375-380.
22. Dubovsky, S. L., J. Christiano, L. C. Daniell et al. (1989). Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch. Gen. Psychiatry 46, 632-638.
23. Ferrari, M. D., J. Odink, K. D. Bos, M. J. Malessy, and G. W. Bruyn (1990). Neuroexitatory amino acids are elevated in migraine. Neurology 40, 1582-1586.
24. Franconi, F., M. Miceli, L. Alberti, G. Seghieri, M. G. De Montis, and A. Tagliamonte (1998). Further insights into the anti aggregating activity of NMDA in human platelets. Br. J. Pharmacol. 124, 35-40
25. Franconi, F., M. Miceli, M. G. De Montis, E. L. Crisafi, F. Bennardini, and A. Tagliamonte (1996). NMDA receptors play an anti aggregating role in human platelets. Thromb. Haemost. 76, 84-87.
26. Gluck, M. R., R. G. Thomas, K. L. Davis, and V. Haroutunian (2002). Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am. J. Psychiatry 159(7), 1165-1173.
27. Goff, D. C., J. Hennen, I. K. Lyoo, G. Tsai, L. L. Wald, A. E. Evins et al. (2002). Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol. Psychiatry 51(6), 493-497.
28. Grant, E. R., B. J. Bacskai, D. E. Pleasure et al. (1997). N-methyl-D-aspartate receptors expressed in a non-neuronal cell line mediate subunit-specific increases in free intracellular calcium. J. Biol. Chem. 272, 647-656.
29. Healy, D. and B. E. Leonard (1987). Monoamine transport in depression: Kinetics and dynamics. J. Affect. Disord. 12(2), 91-103.
30. Heckers, S. and C. Konradi (2002). Hippocampal neurons in schizophrenia. J. Neural. Transm. 109(5-6), 891-905.
31. Javitt, D. C. and S. R. Zukin (1991). The role of excitatory amino acids in neuropsychiatric illness. Am. J. Psychiatry 148, 1301-1308.
32. Kim, J. S., H. H. Kornhuber, W. Schmid-Burgk et al. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
33. Konopka, L. M., R. Cooper, and J. W. Crayton (1996). Serotonin-induced increases in platelet cytosolic calcium in depressives, schizophrenic, and substance abuse patients. Biol. Psychiatry 39, 708-713.
34. Leonard, B. E. (1992). Fundamentals of Psychopharmacology. John Wiley Publishers, Chichester.
35. Maes, M., R. Verkerk, E. Vandoolaeghe, A. Lin, and S. Scharpe (1998). Serum levels of excitatory amino acids, serine glyceine, histidine, threonine, taurine, alanine and arginine in treatment resistant depression: Modulation by treatment with antidepressants and prediction of clinical responsivity. Acta. Psychiatr. Scand. 97, 302-308.
36. Mangano, R. M. and R. Schwarcz (1981). The human platelet as a model for the glutamatergic neuron: Platelet uptake of L-glutamate. J. Neurochem. 36, 1067-1076.
37. Mauri, M. C., A. Ferrara, L. Boscati, S. Bravin, F. Zamberlan, M. Alecci et al. (1998). Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37, 124-129.
38. Mikuni, M., A. Kagaya, K. Takahashi et al. (1992). Serotonin but not norepinephrine induced calcium mobilization of platelets is enhanced in affective disorders. Psychopharmacology 106, 311-314.
39. Nowak, G., Y. Li, and I. A. Paul (1996). Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur. J. Pharmacol. 295, 75-85.
40. Olney, J. E. and N. B. Farber (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52, 998-1007.
41. Pangalos, M. N., A. I. Malizia, P. T. Francis, S. I. Lowe, P. H. Bertolucci, A. W. Procter et al. (1992). Effects of psychotropic drugs on excitatory amino acids in patients undergoing psychosurgery for depression. Br. J. Psychiatry 160, 638-642.
42. Pearse, A. G. E. (1986). The diffuse neuroendocrine system: Peptides, amines, placodes and the APUD theory. Prog Brain Res. 68, 25-31.
43. Reilmann, R., L. H. Rolf, and H. W. Lange, (1994). Huntington's disease: The neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. J. Neurol. Sci. 127, 48-53.
44. Ripova, D., A. Strunecka, V. Nemcova, and I. Farska (1997). Phospholipids and calcium alteration in platelets of schizophrenic patients. Physiol. Res. 46, 59-68.
45. Ripova, D., A. Strunecka, V. Platilova, and C. Hoschl, (1999). Phosphoinositide signalling system in platelets of schizophrenic patients and the effect of neuroleptic therapy. Prostaglandins, Leukot. Essent. Fatty Acids 61, 125-129.
46. Sneddon, J. M. (1973). Blood platelets as a model for monoamine containing neurons. Prog. Neurobiol. 1, 151-198.
47. Stahl, S. M. (1977). The human platelet: A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch. Gen. Psychiatry 34, 509-516.
48. Tsai, G. and Coyle, J. T. (2002). Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42, 165-179.
49. Tsai, G., L. A. Passani, B. S. Slusher et al. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52, 829-836.
50. Ulas, J. and C. W. Cotman (1993). Excitatory amino acid receptors in schizophrenia. Schizophr. Bulle. 19(1), 105-113.